BusinessGalectin Therapeutics to Present at the Singular Research Summer ConferenceBy Nasdaq OMXJul 7, 2017, 4:00 PM UTC
BusinessNewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017By Nasdaq OMXJul 7, 2017, 11:00 AM UTC
BusinessAnthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of SollpuraBy Nasdaq OMXJul 6, 2017, 12:30 PM UTC
BusinessMateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint InhibitorsBy Nasdaq OMXJun 28, 2017, 11:30 AM UTC
BusinessChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory BoardBy Nasdaq OMXJun 27, 2017, 10:30 AM UTC
BusinessNeothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous FatBy Nasdaq OMXJun 26, 2017, 12:01 PM UTC
BusinessPositive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, SpaiBy Nasdaq OMXJun 23, 2017, 11:00 AM UTC
